Egetis Therapeutics (Sweden) Performance
| EGTX Stock | SEK 5.60 0.04 0.71% |
The firm shows a Beta (market volatility) of 0.11, which means not very significant fluctuations relative to the market. As returns on the market increase, Egetis Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Egetis Therapeutics is expected to be smaller as well. Egetis Therapeutics right now shows a risk of 4.19%. Please confirm Egetis Therapeutics semi deviation, coefficient of variation, jensen alpha, as well as the relationship between the downside deviation and standard deviation , to decide if Egetis Therapeutics will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Egetis Therapeutics AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Egetis Therapeutics is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 287.9 M | |
| Total Cashflows From Investing Activities | -6 M |
Egetis |
Egetis Therapeutics Relative Risk vs. Return Landscape
If you would invest 589.00 in Egetis Therapeutics AB on August 29, 2024 and sell it today you would lose (29.00) from holding Egetis Therapeutics AB or give up 4.92% of portfolio value over 90 days. Egetis Therapeutics AB is generating 0.0065% of daily returns and assumes 4.1933% volatility on return distribution over the 90 days horizon. Simply put, 37% of stocks are less volatile than Egetis, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Egetis Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Egetis Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Egetis Therapeutics AB, and traders can use it to determine the average amount a Egetis Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0016
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | EGTX |
Estimated Market Risk
| 4.19 actual daily | 37 63% of assets are more volatile |
Expected Return
| 0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Egetis Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Egetis Therapeutics by adding Egetis Therapeutics to a well-diversified portfolio.
Egetis Therapeutics Fundamentals Growth
Egetis Stock prices reflect investors' perceptions of the future prospects and financial health of Egetis Therapeutics, and Egetis Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Egetis Stock performance.
| Return On Equity | -0.26 | |||
| Return On Asset | -0.14 | |||
| Operating Margin | (7.54) % | |||
| Current Valuation | 698.73 M | |||
| Shares Outstanding | 249.59 M | |||
| Price To Book | 1.52 X | |||
| Price To Sales | 42.39 X | |||
| Revenue | 38.24 M | |||
| EBITDA | (101.9 M) | |||
| Cash And Equivalents | 207.41 M | |||
| Cash Per Share | 1.26 X | |||
| Total Debt | 4.88 M | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 2.71 X | |||
| Cash Flow From Operations | (130.11 M) | |||
| Earnings Per Share | (0.70) X | |||
| Total Asset | 569.27 M | |||
About Egetis Therapeutics Performance
Assessing Egetis Therapeutics' fundamental ratios provides investors with valuable insights into Egetis Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Egetis Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Egetis Therapeutics AB , a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rareniche diseases with unmet medical needs in the orphan drug segment. Egetis Therapeutics AB was founded in 2006 and is based in Stockholm, Sweden. Egetis Therapeutics operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 11 people.Things to note about Egetis Therapeutics performance evaluation
Checking the ongoing alerts about Egetis Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Egetis Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Egetis Therapeutics had very high historical volatility over the last 90 days | |
| Egetis Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 38.24 M. Net Loss for the year was (104.54 M) with loss before overhead, payroll, taxes, and interest of (58.28 M). | |
| Egetis Therapeutics AB has accumulated about 207.41 M in cash with (130.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.26. | |
| Roughly 52.0% of the company shares are held by company insiders |
- Analyzing Egetis Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Egetis Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Egetis Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Egetis Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Egetis Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Egetis Therapeutics' stock. These opinions can provide insight into Egetis Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Egetis Stock Analysis
When running Egetis Therapeutics' price analysis, check to measure Egetis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Egetis Therapeutics is operating at the current time. Most of Egetis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Egetis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Egetis Therapeutics' price. Additionally, you may evaluate how the addition of Egetis Therapeutics to your portfolios can decrease your overall portfolio volatility.